Deceased organ donor research: The last research frontier?

Liver Transplantation

Volumn 19, Issue 2, 2013, Pages 118-121

  Mone, Thomas ^c   Heldens, John ^a   Niemann, Claus U ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c OneLegacy   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCYSTEINE;

CLINICAL RESEARCH; EVIDENCE BASED MEDICINE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; INFORMED CONSENT; MEDICAL DOCUMENTATION; ORGAN DONOR; PATIENT MONITORING; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK FACTOR;

ACETYLCYSTEINE; ANTIOXIDANTS; FEMALE; GRAFT SURVIVAL; HUMANS; LIVER TRANSPLANTATION; MALE; TISSUE AND ORGAN HARVESTING;

EID: 84873667461     PISSN: 15276465     EISSN: 15276473     Source Type: Journal    
DOI: 10.1002/lt.23579     Document Type: Review

References (9)

1. Malinoski DJ, Patel MS, Daly MC, Oley-Graybill C, Salim A,; for UNOS Region 5 DMG Workgroup. The impact of meeting donor management goals on the number of organs transplanted per donor: results from the United Network for Organ Sharing region 5 prospective donor management goals study. Crit Care Med 2012; 40: 2773-2780.
2. Dikdan GS, Mora-Esteves C, Koneru B,. Review of randomized clinical trials of donor management and organ preservation in deceased donors: opportunities and issues. Transplantation 2012; 94: 425-441.
3. Schnuelle P, Gottmann U, Hoeger S, Boesebeck D, Lauchart W, Weiss C, et al. Effects of donor pretreatment with dopamine on graft function after kidney transplantation: a randomized controlled trial. JAMA 2009; 302: 1067-1075.
4. Kotsch K, Ulrich F, Reutzel-Selke A, Pascher A, Faber W, Warnick P, et al. Methylprednisolone therapy in deceased donors reduces inflammation in the donor liver and improves outcome after liver transplantation: a prospective randomized controlled trial. Ann Surg 2008; 248: 1042-1050.
5. D'Amico F, Vitale A, Frigo AC, Piovan D, Bertacco A, Bassi D, et al. Use of N-acetylcysteine during liver procurement: a prospective randomized controlled study. Liver Transpl 2013; 18: 135-144.
6. Feng S,. Donor intervention and organ preservation: where is the science and what are the obstacles? Am J Transplant 2010; 10: 1155-1162.
7. ACT Investigators. Acetylcysteine for prevention of renal outcomes in patients undergoing coronary and peripheral vascular angiography: main results from the randomized Acetylcysteine for Contrast-Induced Nephropathy Trial (ACT). Circulation 2011; 124: 1250-1259.
8. Birck R, Krzossok S, Markowetz F, Schnülle P, van der Woude FJ, Braun C,. Acetylcysteine for prevention of contrast nephropathy: meta-analysis. Lancet 2003; 362: 598-603. (Pubitemid 37013299)
9. National Science Foundation. 45 CFR part 690: federal policy for the protection of human subjects (same as 45 CFR part 46, which pertains to HHS). Subpart A: the common rule for the protection of human subjects. http://www.nsf.gov/bfa/dias/policy/docs/45cfr690.pdf. Accessed November 2012.